Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia

Aim: To assess the efficacy and safety of an intravitreal injection of bevacizumab ( Avastin (R)) for myopic choroidal neovascularisation ( mCNV). Methods: Intravitreal bevacizumab ( 1 mg) was injected into eight eyes of eight patients with mCNV in this non-randomised, interventional case series. The best-corrected visual acuity ( BCVA) was measured and the optical coherence tomography ( OCT) and fluorescein angiography findings were examined before and after treatment. The minimum follow-up time was 3 months. Results: The mean BCVA was 0.26 before treatment and 0.51 at the last visit ( p = 0.009). The BCVA improved to two or more lines in six eyes ( 75%) and remained the same in two eyes ( 25%). Leakage from the mCNV on fluorescein angiography decreased in seven eyes ( 87.5%). The choroidal neovascularisation area on fluorescein angiography ( p = 0.049) and the foveal thickness on OCT images decreased significantly ( p = 0.027) after the treatment. No major complications developed. Conclusion: Intravitreal injection of bevacizumab seems to be an effective and safe treatment for mCNV.